Acquiring Company
Fulcrum Therapeutics
Acquired Company
Slate Medicines
CambridgeRaleighBiotechnologyHealth CareTherapeuticsPharmaceuticalBiopharmaBiotechnologyHealth CareDescription
Fulcrum Therapeutics has agreed to merge with Slate Medicines in a stock-for-stock transaction, supported by a $245 million financing. Following the merger, pre-merger Slate holders will own approximately 55.9% of the combined entity. The merger aims to unite platforms and secure growth for the newly formed company.
Don't miss Fulcrum Therapeutics's next move
Get an email the moment Fulcrum Therapeutics makes an acquisition, hires an exec, or expands — usually minutes after it happens.
One email per event. Unsubscribe anytime.
Related People
M&A Insights
Based on deal dataFrequently asked
Who acquired Slate Medicines?
Slate Medicines was acquired by Fulcrum Therapeutics, based in Cambridge. The deal was reported on August 17, 2026. Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases. Fulcrum Therapeutics is publicly traded (FULC) and operates in Biotechnology.
When did Fulcrum Therapeutics acquire Slate Medicines?
Fulcrum Therapeutics's acquisition of Slate Medicines was reported on August 17, 2026. Fulcrum Therapeutics has agreed to merge with Slate Medicines in a stock-for-stock transaction, supported by a $245 million financing. Following the merger, pre-merger Slate holders will own approximately 55.9% of the combined entity. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Slate Medicines do?
Slate Medicines, Inc. is a biotech company focused on advancing next generation therapeutics for migraine and other headache disorders. It is privately held, operating in Biotechnology, and is based in Raleigh.